BSX - Boston Scientific Corporation
38.46 0.00 (0.00%)
After hours: 4:34PM EDT
| Previous Close | 37.97 |
| Open | 38.38 |
| Bid | 38.44 x 800 |
| Ask | 38.46 x 1100 |
| Day's Range | 37.76 - 38.65 |
| 52 Week Range | 31.56 - 43.84 |
| Volume | 9,630,350 |
| Avg. Volume | 6,032,981 |
| Market Cap | 53.574B |
| Beta (3Y Monthly) | 0.69 |
| PE Ratio (TTM) | 38.85 |
| EPS (TTM) | 0.99 |
| Earnings Date | Oct 23, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 48.17 |
- Insider Monkey
Hedge Funds Have Never Been This Bullish On Boston Scientific Corporation (BSX)
There are several ways to beat the market, and investing in small cap stocks has historically been one of them. We like to improve the odds of beating the market further by examining what famous hedge fund operators such as Jeff Ubben, George Soros and Carl Icahn think. Those hedge fund operators make billions of […]
- Zacks
Abbott (ABT) Gets FDA Nod for New Troponin-I Blood Test
The regulatory go-ahead for Abbott's (ABT) ARCHITECT STAT High Sensitivity Troponin-I blood test is a major stride forward in its commitment for detecting patients suspected of having a heart attack.
- Zacks
Abiomed's (ABMD) Impella 5.5 With SmartAssist Gets FDA Nod
Abiomed's (ABMD) flagship Impella heart pump line is a major growth driver.
- Zacks
Medtronic Upbeat on Drug-Eluting Stents in Patients With DAPT
Medtronic's (MDT) DAPT study's robust data outcome is likely to aid as the therapy duration might prove to be a superior treatment option.
- Zacks
PETQ vs. BSX: Which Stock Is the Better Value Option?
PETQ vs. BSX: Which Stock Is the Better Value Option?
- PR Newswire
Boston Scientific Announces Conference Call Discussing Third Quarter 2019 Financial Results
MARLBOROUGH, Mass. , Oct. 1, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended ...
- Zacks
Boston Scientific (BSX) Upbeat on Results of EVOLVE Study
Boston Scientific (BSX) is hopeful about robust data outcome on DAPT study as the therapy duration might prove to be a superior treatment option.
- Investopedia
8 'Low Beta' Growth Stocks That Can Lead Amid Market's Turmoil
Low beta growth stocks, those that are more stable than the market as a whole, historically outperform when investors become more risk averse.
- PR Newswire
Boston Scientific Announces Positive Data from the EVOLVE Short DAPT study with the SYNERGY™ Bioabsorbable Polymer Stent
SAN FRANCISCO and MARLBOROUGH, Mass., Sept. 26, 2019 /PRNewswire/ -- Boston Scientific (BSX) has announced primary endpoint results from the EVOLVE Short DAPT clinical trial, the first prospective study initiated in the U.S. to examine the safety of a shortened duration of dual antiplatelet therapy (DAPT) in patients at high risk for bleeding. Results were presented during a late-breaking clinical science session at the 31st Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, in San Francisco, and demonstrated that a three-month regimen of DAPT is non-inferior to a 12-month or longer regimen in patients with an increased risk of bleeding after being treated with the SYNERGY™ Bioabsorbable Polymer (BP) Stent.
- TipRanks
3 “Strong Buy” Med Tech Stocks Amid Recession Threat
The recession alarm bells have been sounded. Many investors fear that we are heading towards a recession as a result of the inversion of the yield curve, a key recession indicator, as well as the ongoing trade war with China According to CFO’s polled by Duke University, these fears are justified. Based on the survey, 53% of U.S. CFOs believe the market will enter into a recession by the 2020 elections. Two thirds predict a recession will come by year-end 2020. “Business optimism has not been this low since September 2016, a time when the unemployment rate was 5%. Optimism is low in all regions of the world, which exacerbates any slowdown occurring in the US,” John Graham, a finance professor at Duke University who directed the study, stated.That being said, large-cap med tech stocks have outperformed the S&P 500 year-to-date while small and mid-cap stocks have surpassed the Russell 2000 over the same time period. With this in mind, Needham’s Michael Matson stated on September 24 that he believes 3 med tech stocks have earned a “Strong Buy” rating despite the rising recession risk. This is a rating Needham gives to stocks that have especially strong long-term growth narratives. Using data from TipRanks, we wanted to dig a little deeper to determine if the five-star analyst’s picks really are poised to outperform. Let’s dive in. Boston Scientific CorporationDespite some recent shakiness, Boston Scientific (BSX\- Get Report) has gained 19% year-to-date, with Matson expecting even more growth regardless of the economic climate. The med tech company manufactures medical devices such as defibrillators and pacemakers to provide patients with less invasive medical solutions. However, Matson does point out that one of BSX’s strengths is its structural heart products which could fuel significant sales for the company. Back in April, BSX received FDA approval for its LOTUS Edge Aortic Valve System that uses transcatheter aortic valve replacement (TAVR) technology to treat severe aortic stenosis, or the narrowing of the aortic valve opening. Adding to the good news, its WATCHMAN left atrial appendage closure device reached 100,000 patient implants globally as of September 18. The company has also made significant progress in terms of its efforts to expand its interventional oncology, arterial and venous therapy product offerings. BSX completed its $4.2 billion acquisition of BTG plc on August 26 in order to expand its reach in these areas. “Over the longer-term, we think that the BTG deal has the potential to be accretive to BSX’s revenue growth and margins,” Matson commented. He adds that its limited capital equipment sales exposure makes it less vulnerable in a recession. As a result, the five-star analyst rated BSX a “Strong Buy” and maintained the $53 price target. He believes share prices could surge 26% over the next twelve months, which is the highest upside predicted out of all other analysts covering the stock.All in all, Wall Street echoes the analyst’s sentiment. 15 Buy ratings vs 2 Holds assigned in the last three months add up to a ‘Strong Buy’ analyst consensus. Its $49 average price target indicates 15% upside potential.See BSX’s price targets and analyst ratings on TipRanks. Zimmer Biomet HoldingsZimmer Biomet (ZBH\- Get Report) develops medical technologies to treat patients suffering from bone, joint and supporting soft tissue injuries or disorders. Similar to BSX, Matson highlights ZBH as one of his top med tech picks in spite of its recent dip as less of its sales come from capital equipment. The company, which is up 32% year-to-date, has attracted a lot of attention thanks to its new robotics system. Back in March, ZBH announced that it received FDA 501(k) clearance for its Rosa One Spine system for robotically-assisted surgery. Rosa helps surgeons perform thoracolumbar minimally invasive and complex spine procedures. Partly due to the limited launch of Rosa, ZBH saw its knee segment best growth in three years, with the company planning to increase its investments in its robotics segment in the second half of the year. “Importantly, even when excluding ROSA sales in the quarter, our global knee business delivered positive growth, accelerated growth sequentially and further narrowed our gap to market,” CEO Bryan Hanson noted.While Zimmer has been bogged down by quality and supply issues, it has made progress in resolving them. Supply chain improvements that are expected to run through the inventory channel and additional product launches could drive significant upside for the company. On September 16, Zimmer announced that it received FDA 501(k) clearance for the JuggerStitch meniscal repair device. Just a few days later, it reached a distribution agreement with Align Technology (ALGN) for its dental scanners. Based on all of the above factors, Matson picks ZBH as his second “Strong Buy” and maintained his $170 average price target. His price target is highest out of all the analysts covering ZBH and suggests 24% upside potential.The rest of the Street is on the same page. With 14 Buy ratings compared to 2 Holds and 1 Sell received in the last three months, ZBH has a ‘Strong Buy’ analyst consensus. The average price target of $152 implies 10% upside potential. See ZBH’s price targets and analyst ratings on TipRanks. Medtronic PlcWhile Medtronic (MDT\- Get Report) shares are also down in the last five days, Matson argues that the company is still expected to see strong long-term growth on top of its 18% year-to-date jump. MDT is the largest medical device company in the world and creates medical solutions for cardiac disorders, diabetes, minimally invasive therapies and restorative therapies. In an attempt to keep up with competitors, MDT unveiled its Hugo robot-assisted surgery system on September 24. Management believes the system, which is expected to be launched outside of the U.S. next year, is more flexible and cost-effective than other technologies on the market.While some believe the financial projections for Hugo leave something to be desired, several analysts disagree. As the surgical robotics market is largely underpenetrated at about 2%, the space represents a significant opportunity for MDT. Additionally, it announced on September 23 that its Evolut Pro+ TAVR device has been approved by the FDA for use in patients at low risk from open valve replacement surgery. Evolut is an updated version of its valve product. All of these positive developments prompted Matson to pick MDT and maintain the $133 price target, the highest out of all the Wall Street analysts that have assigned a rating to the stock. His price target conveys his confidence in MDT’s ability to climb 24% over the next twelve months.In general, Wall Street takes a similar approach when it comes to MDT. It has a ‘Strong Buy’ analyst consensus as it has received 16 Buy ratings vs 5 Holds in the last three months. Shares could rise 9% in the next twelve months based on its $117 average price target. See MDT’s price targets and analyst ratings on TipRanks.
- Simply Wall St.
Boston Scientific Corporation (NYSE:BSX) Insiders Have Been Selling
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
- Barrons.com
10 Stable Growth Stocks That Are Still Worth the Price, According to an Analyst
What separates winners from losers, UBS strategist Francois Trahan said, is “beta”—a volatility metric measuring how much a stock deviates from the market’s movement. Think Facebook, Alphabet and Boston Scientific.
- PR Newswire
Boston Scientific Announces Scheduled Presentations at Transcatheter Cardiovascular Therapeutics 2019
MARLBOROUGH, Mass. , Sept. 18, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced key data that will be presented at the 31st Transcatheter Cardiovascular Therapeutics (TCT), ...
- Zacks
BAX or BSX: Which Is the Better Value Stock Right Now?
BAX vs. BSX: Which Stock Is the Better Value Option?
- Zacks
IoMT Becomes the Buzzword in New Age MedTech Investing
Increasing adoption of cloud platforms, phones, phablets, tablets and other smart devices as well as apps is making acceptance of IoMT easier among the masses.
- TipRanks
Morgan Stanley: Buy These 3 Stocks on Recent Weakness
Investors are always looking for stocks that represent compelling investment opportunities but finding them isn’t always an easy task. That being said, Wall Street’s top investment firms can provide helpful insights as to which stocks boast a strong long-term growth narrative. Top analysts from Morgan Stanley have released updates on a few stocks that do just that.The firm recently issued recommendations on 3 stocks, highlighting each as presenting a unique buying opportunity given recent weakness. Each boasts significant support from the rest of the Street as well as potential for substantial long-term upside.Bearing this in mind, we used TipRanks’ investing tools to take a closer look at Morgan Stanley’s 3 picks. Here’s what we found out. Uber Technologies Inc. (UBER)It’s no question that it has been a bumpy ride for Uber since going public. As of its May 10 IPO date, shares are down 20% with some investors expressing their concern that recent headwinds will further delay a turnaround.Uber has been bogged down by costs related to its public offering. On August 8, the company reported a second quarter loss of $5.2 billion, its largest ever quarterly loss, as a result of $3.9 billion worth of stock-based compensation expenses it incurred from the IPO. Even without those expenses, the ride sharing company still lost approximately $1.3 billion. However, management points out that its heavy investments in Uber Freight, food delivery and price reductions in its ride-hailing business can be attributed to the loss.New regulation in California also threatens to derail Uber’s plans to reach profitability. California senators will vote on Assembly Bill 5 (AB5) this month which if passed, would make it more difficult for gig economy companies to classify workers as independent contractors. This would force Uber to consider drivers employees, which would adversely affect business.That being said, Uber could pass the added costs along to consumers in order to offset some of the impacts of AB5. Not to mention the company stated on September 6 that it plans to invest $200 million per year in its fasting growing segment, Uber Freight. One top analyst, Brian Nowak, argues that Uber has multiple ways to offset the headwind of AB5 being approved. “We expect Uber to pass through most of the higher costs to consumers and minimize the cash flow headwind…balancing the incremental costs Uber will bear with the expected impact on consumer demand from higher fares. This will come at a cost with an estimated 2021 negative financial impact ranging from 6-16% of contribution profit,” he explained. As a result, the five-star analyst reiterated his Buy rating and $57 price target on September 5. He thinks shares have the potential to surge 59% in the next twelve months.All in all, Wall Street is bullish on the ride sharing platform. Uber boasts a ‘Strong Buy’ analyst consensus and a $54 average price target, indicating 61% upside potential. Domino's Pizza, Inc. (DPZ)While the pizza delivery chain hasn’t been shy about acknowledging the threat of third-party delivery services in recent quarters, Morgan Stanley tells investors to keep putting DPZ on their plates even though shares have dropped 1% year-to-date. Domino’s Pizza invited several Wall Street analysts including Morgan Stanley’s John Glass to its “innovation garage” on September 6. The event showcased its new innovation and technology initiatives, with the analyst telling investors he remains convinced the company is set to serve up long-term gains.While DPZ didn’t actually reveal anything brand new at the event, it did go a long way to renew the analyst’s confidence in the pizza chain. Among his takeaways from the event, Glass highlighted the fact that management maintained that it will be able to meet its three to five year same store sales guidance of 3% to 6% growth. Domino’s expects to achieve this thanks to several of its near-term initiatives. As part of these initiatives, DPZ will start offering better carryout options as well as 20% off all orders placed after 9 p.m. Adding to the good news, its GPS tracking is expected to be launched systemwide by the end of 2019. The company will also start testing autonomous vehicles to provide a cheaper delivery option for customers as they won’t need to tip. Glass sees all of the above as steps in the right direction. “Unlike a typical analyst meeting, this event didn't break new news, but what we did hear was generally positive as management outlined some more specific near-term steps to drive domestic sales,” he explained. As a result, the four-star analyst reiterated his Buy rating and $287 price target on September 9. The price target demonstrates Glass’ confidence in DPZ’s ability to gain 17% over the next twelve months.With 14 Buy ratings vs 7 Holds and 1 Sell assigned over the last three months, the word on the Street is that DPZ is a ‘Moderate Buy’. Its $285 average price target suggests 16% upside potential. Boston Scientific Corporation (BSX)The last stock on our list manufactures medical devices designed to provide less invasive medical solutions. Its devices include defibrillators, pacemakers as well as many other products for interventional medical specialties. While shares have declined 0.14% in the last month, Morgan Stanley’s David Lewis tells investors BSX shares are poised for long-term gains.According to BSX’s July 24 Q2 earnings release, the company looks solid. It generated quarterly sales of $2.6 billion, up 5.6% on a reported basis and 6.3% on an organic basis from the year-ago quarter. Management attributes this to revenue growth across all segments.The company’s latest acquisitions and new products are expected to drive even more growth. On August 26, BSX finalized its $4.2 billion acquisition of BTG plc, helping BSX expand its interventional oncology, arterial and venous therapy product offerings. It also acquired Vertiflex Inc. back in June, which designed a minimally-invasive device to improve physical function and reduce pain in patients with lumbar spinal stenosis, or the narrowing of the spinal canal.Not to mention BSX announced the FDA approval for its ImageReady MRI labeling for the Vercise Gevia Deep Brain Stimulation (DBS) system in an MRI environment on August 19. The system, along with the Vercise Cartesia Directional Lead, was developed to treat symptoms of Parkinson’s Disease, a progressive nervous system disorder that can cause shaking, muscle stiffness and slow movement. It’s estimated that 10 million people are affected by the debilitating disease globally.All of these positive developments contributed to Lewis’ conclusion that BSX’s long-term growth narrative remains strong. As a result, he reiterated his Buy rating and $50 price target on August 29. The four-star analyst sees 20% upside potential for the company. All in all, the rest of the Street mirrors the analyst’s sentiment. Boston Scientific boasts a ‘Strong Buy’ Street consensus as well as a $49 average price target, implying 16% upside potential. Discover the Street’s best-rated stocks with the Top Analysts’ Stocks tool
- InvestorPlace
3 Big Stock Charts for Tuesday: Boston Scientific, GM and United Airlines
The bulls tried to revive the rally from last week as the new trading week began, but no dice. The S&P 500 essentially broke even on Monday, as investors remain on the fence about the true strength of the global economy.Source: Shutterstock Twilio (NYSE:TWLO) held the broad market back more than any other name, falling more than 9% after shareholders renewed doubts about the future of the cloud-based digital customer service middleman.At the other end of the spectrum, Bank of America (NYSE:BAC) and AT&T (NYSE:T) worked just a little bit harder. Shares of the telecom outfit ended the day up nearly 1.5% after activist investment group Elliott Management took on a stake and began clamoring for improvements. Meanwhile, BofA shares shot higher to the tune of 3%, leading an industry-wide rally spurred by a healthy rise in interest rates.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Stocks to Sell in Market-Cursed September As for the stock charts that merit a closer inspection headed into Tuesday's session though, take a look at Boston Scientific (NYSE:BSX), General Motors (NYSE:GM) and United Airlines Holdings (NASDAQ:UAL). Here's why. General Motors (GM)General Motors hasn't been an easy name to own -- or hold onto -- for several years now. Aside from the sheer day-to-day volatility, GM stock has made some alarmingly big selloffs even since the 2008 recovery. Not even the auto-buying frenzy that lead to "peak auto" proved beneficial for the stock.There has been a method to the madness the whole time though, even if it has been tough to ferret out. The trick, taking a huge step back and putting the near-term action in context. * Click to EnlargeThe long-term view of the weekly chart makes clear that last year's reversal is the result of an encounter with a support line that extends all the way back to 2012 low (not shown). * The travel within that rising trading range, however, is range-bound in and of itself. Since late last year, GM stock has moved coherently through a rising trading range as well, framed in red on both stock charts. * Assuming the recent range-bound action and push up and off the long-term support line is part of a pattern, General Motors shares could rally to nearly $50 before bumping into technical resistance again. United Airlines Holdings (UAL)With nothing more than a quick glance, United Airlines Holdings shares just look like they're trapped in a trading range, content to drift sideways in a choppy manner. And, perhaps that's all the past several weeks are, and will continue to be into the future.But, given the stock's history and the context of the current action -- and where the subtle turn seems to be taking shape -- it would be naive to ignore a distinct possibility here. A major bullish move could be in the works. * 7 Low-Risk Mutual Funds to Buy Now * Click to EnlargeThe daily chart indicates a couple of resistance lines and one key support level, all plotted in yellow, making for a well-established trading range. That sideways action could be fanning some flames for a breakout thrust though. * The prod for that thrust is easier to identify on the weekly chart, however. June's kiss of the lower boundary of the rising trading range going back to 2016 spurred a reversal that was renewed last months. * The context in question is the similarity of the action since the beginning of this year and the choppiness from early last year. The latter results in a move to the upper edge of the trading range. Boston Scientific (BSX)As of Friday's close, Boston Scientific shares looked like they were breaking out of a narrowing wedge pattern that started to take shape in June. It's plotted in yellow on the daily chart. BSX closed above the upper boundary as of the end of last week. But, perhaps that move was the last headfake before shares finally rollover and make a move to the downside that has actually been brewing for months.Fortunately, there are two plausible floors that will catch any pullback that gets rolling here. Unfortunately, neither is particularly close, and one is well below the stock's current value. * Click to EnlargeThe sheer scope of Monday's reversal is telling. A little bit of a gain and hint of a breakout move enticed would be buyers, but shares plunged under the blue 20-day and purple 50-day moving average lines yesterday. * There are two prospects for a downside target. The upper one is around $37.60, where the near-term technical floor made by connecting last year's key lows can be found. The other is at $31.30, made by lining up the key lows between 2014 and 2018, marked in red. * The daily chart's floor at $41.27, or the lower end of the trading range made since June, is the last bastion of hope for the time being.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about him at his website jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks to Sell in Market-Cursed September * 7 of the Worst IPO Stocks in 2019 * 7 Best Stocks That Crushed It This Earnings Season The post 3 Big Stock Charts for Tuesday: Boston Scientific, GM and United Airlines appeared first on InvestorPlace.
- Simply Wall St.
Does Boston Scientific Corporation's (NYSE:BSX) CEO Pay Reflect Performance?
Mike Mahoney has been the CEO of Boston Scientific Corporation (NYSE:BSX) since 2012. First, this article will compare...
- Zacks
Boston Scientific Closes BTG Buyout, PI Arm to Get a Boost
In its effort to accommodate the acquisition of BTG, Boston Scientific (BSX) is offloading its certain non-prior businesses.
- Zacks
Boston Scientific (BSX) Up 1.6% Since Last Earnings Report: Can It Continue?
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
BAX vs. BSX: Which Stock Is the Better Value Option?
BAX vs. BSX: Which Stock Is the Better Value Option?
- PR Newswire
Boston Scientific to Participate in the 2019 Wells Fargo Securities Healthcare Conference
MARLBOROUGH, Mass. , Aug. 20, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2019 Wells Fargo Securities Healthcare Conference on Thursday, September ...
- Zacks
Boston Scientific's (BSX) Vercise Gevia DBS Gets FDA Nod
Boston Scientific's (BSX) Vercise Gevia DBS system should boost neuromodulation revenues for the company.
- Zacks
Here's Why You Should Hold Varian Medical (VAR) Stock Now
Varian (VAR) raises the revenue guidance for fiscal 2019.
- PR Newswire
Boston Scientific Announces FDA Approval Of ImageReady™ MRI For Vercise Gevia™ Deep Brain Stimulation System
MARLBOROUGH, Mass., Aug. 19, 2019 /PRNewswire/ -- Boston Scientific Corporation (BSX) announced the U.S. Food and Drug Administration (FDA) approval of its ImageReady™ MRI labeling for the Vercise Gevia™ Deep Brain Stimulation (DBS) System to be used in a full-body magnetic resonance imaging (MRI) environment.1 This system, with the Vercise Cartesia™ Directional Lead, is designed to treat the symptoms of Parkinson's Disease (PD) by delivering precisely targeted electrical stimulation in the brain to provide optimal symptom relief and better control of unwanted side effects.
